US Executive Compensation Proxy SEC Filings — April 15, 2026
Across 46 DEF 14A proxy statements for US SEC-listed firms, primarily small/mid-cap tech, biotech, financials, and materials companies, neutral sentiment dominates (34/46 neutral), with positive highlights in 6 filings showcasing robust 2025 revenue growth (e.g., Dexcom +16% YoY to $4.66B, Martin Marietta +$6.2B record revenues) and margin expansion, contrasted by mixed signals in 5 cases like auditor changes and remediated control weaknesses. Period-over-period trends reveal strong performers in healthcare/biotech (Dexcom net income +45% YoY) and materials (Martin Marietta aggregates GP/ton +12-16%), while others show exec pay volatility (Carter Bankshares CEO +3.7% YoY, others -0.6% to -4.2%). Capital allocation favors shareholder returns (Dexcom $500M buybacks, Martin Marietta $647M incl 5% div hike), with frequent equity plan expansions signaling growth conviction. Forward-looking data sparse but includes FiscalNote FY2026 EBITDA guide $14-16M and multiple reverse splits/authorized share hikes as dilution risks. All filings cluster annual meetings May-June 2026 as key catalysts for say-on-pay, director elections, and auditor votes, with virtual formats standard. Portfolio-level pattern: 7/46 disclose YoY financial outperformance amid board refreshes, implying stable governance but watch for say-on-pay pushback in high-comp firms.